HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort.

Corrigendum to 'Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE)': [ESMO Open. Volume 10, Issue 2, February 2025, 104126

MYC rearrangement improves the predictive efficacy of the double-hit model in newly diagnosed multiple myeloma.

Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer.

Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort.

Corrigendum to 'Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE)': [ESMO Open. Volume 10, Issue 2, February 2025, 104126

MYC rearrangement improves the predictive efficacy of the double-hit model in newly diagnosed multiple myeloma.

Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer.

Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.